SKYE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SKYE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Skye Bioscience's Ending Cash Position for the quarter that ended in Mar. 2024 was $92.42 Mil.
Skye Bioscience's quarterly Ending Cash Position declined from Sep. 2023 ($14.21 Mil) to Dec. 2023 ($10.34 Mil) but then increased from Dec. 2023 ($10.34 Mil) to Mar. 2024 ($92.42 Mil).
Skye Bioscience's annual Ending Cash Position declined from Dec. 2021 ($8.99 Mil) to Dec. 2022 ($1.25 Mil) but then increased from Dec. 2022 ($1.25 Mil) to Dec. 2023 ($10.34 Mil).
The historical data trend for Skye Bioscience's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Ending Cash Position | Get a 7-Day Free Trial | 1.84 | 2.47 | 8.99 | 1.25 | 10.34 |
Skye Bioscience Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Ending Cash Position | Get a 7-Day Free Trial | 2.67 | 0.56 | 14.21 | 10.34 | 92.42 |
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Skye Bioscience's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as
Ending Cash Position | = | Beginning Cash Position | + | Net Change in Cash |
= | 1.25 | + | 9.087 | |
= | 10.34 |
Skye Bioscience's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as
Ending Cash Position | = | Beginning Cash Position | + | Net Change in Cash |
= | 10.336 | + | 82.087 | |
= | 92.42 |
Thank you for viewing the detailed overview of Skye Bioscience's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.
Punit Dhillon | director | 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
John D Diekman | 10 percent owner | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Partners Vii, Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Paul A. Grayson | director | 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
5am Ventures Vii, L.p. | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Kush Parmar | 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Partners Ii, Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Co-investors Ii Lp | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Versant Ventures Iii, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Scott M Rocklage | 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Andrew J. Schwab | director, 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Versant Side Fund Iii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
5am Ventures Ii Lp | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Versant Venture Capital Iii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Deborah H. Charych | director | 1001 17TH ST, SAN FRANCISCO CA 94107 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-24-2023
By GuruFocusNews GuruFocusNews • 01-10-2022
By GuruFocusNews GuruFocusNews • 06-17-2022
By Marketwired Marketwired • 10-12-2021
By GuruFocusNews GuruFocusNews • 03-03-2022
By Marketwired Marketwired • 10-07-2021
By GuruFocusNews GuruFocusNews • 12-15-2021
By PurpleRose PurpleRose • 07-21-2022
By GuruFocusNews GuruFocusNews • 06-07-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.